Delivery Order SPE2DB24D9222-SPE2DB24FAZFM
Award Date
8/8/24
Potential Completion Date
8/29/24
Potential Value
$48K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $120,428.55 to provide 4,566,597,117 units of Keytruda 100 mg/4 ml vial. The contract is a firm fixed-price award from the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of December 20, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of Keytruda 100 mg/4 ml vial 4 ml to the Defense Logistics Agency (DLA). The contract is a firm fixed-price delivery order with a ceiling value of $32,114.28 and an ultimate completion date of September 19, 2024. DMS Pharmaceutical Group holds a larger, single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs...
This is a federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The $82,041.50 firm-fixed-price delivery order contract is for the supply of KEYTRUDA 100 MG/4 ML VIAL 4ML, a pharmaceutical product. This award is not associated with a set-aside designation. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) for the delivery of Keytruda 100 mg/4 ml vials. The $40,109.20 firm fixed-price delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group to provide a comprehensive range of pharmaceutical products to support the recurring medical supply needs of Department of Defense...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the delivery of Keytruda 100 mg/4 ml vial 4 ml to the U.S. government. The contract, valued at $48,171.42, is a firm fixed-price delivery order with no set-aside designation, awarded by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under the DLA's SPE2DB Indefinite Delivery Contract (IDC) valued at $499,999,999. The award, valued at $77,505.20, is for the supply of Keytruda 100 mg/4 ml vial to the Defense Logistics Agency (DLA), which supports the medical needs of military healthcare facilities. The contract is a firm fixed-price delivery order with a completion date of February 2, 2023. DMS Pharmaceutical...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, provides for the delivery of Keytruda 100 mg/4 ml vial, a cancer medication, to the Defense Logistics Agency (DLA). The $32,114.28 firm fixed-price delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. This IDC allows the DLA to issue delivery orders for a wide range of...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) to provide a wide range of pharmaceutical products and medical supplies to military health facilities. The contract, valued at up to $40,109.20, is for the delivery of Keytruda 100 mg/4 ml vial, a cancer medication, with a performance period through July 8, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price delivery order valued at $77,505.20. The award was made by the Defense Logistics Agency (DLA), a defense agency, to provide 4,559,957,331 units of the prescription drug Keytruda 100 mg/4 ml vial with a 4 ml fill. The contract has an ultimate completion date of March 8, 2023. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) for the delivery of Keytruda 100 mg/4 ml vial 4 ml. The $77,505.20 firm-fixed-price delivery order contract has a completion date of January 31, 2023. DMS Pharmaceutical Group is a key pharmaceutical supplier to the U.S. Department of Defense, having secured a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program to provide a...